试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-29
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)
编号:NCT03033511登记状态:提前终止企业 / 申办者:AbbVie
药物 / 成分:Placebo for dexamethasone、Placebo for rovalpituzumab tesirine、Rovalpituzumab tesirine、Dexamethasone
登记的停止原因(原文):Independent Data Monitoring Committee recommendation
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-29
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01
编号:NCT03285308登记状态:提前终止企业 / 申办者:Allergan
药物 / 成分:Placebo、Relamorelin
登记的停止原因(原文):The Relamorelin program is being terminated solely based on a business decision.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-29
A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia
编号:NCT03381833登记状态:提前终止企业 / 申办者:La Jolla Pharmaceutical Company
药物 / 成分:LJPC-401、LJPC-401
登记的停止原因(原文):Terminated early for lack of efficacy as determined by interim endpoint analyses
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-28
A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma
编号:NCT00359294登记状态:提前终止企业 / 申办者:PharmaMar
药物 / 成分:PM00104
登记的停止原因(原文):Low recruitment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-28
Intranasal Dexmedetomidine for Procedural Pain Management in Elderly Adults in Palliative Care
编号:NCT03151863登记状态:提前终止企业 / 申办者:Walid HABRE
药物 / 成分:Opioids、Dexmedetomidine、Placebo
登记的停止原因(原文):Lack of budget
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-28
Novel Strategies to Improve Immunomodulation and Non-invasive Clinical Monitoring in VCA
编号:NCT03241719登记状态:提前终止企业 / 申办者:Brigham and Women's Hospital
药物 / 成分:IL-2
登记的停止原因(原文):No participants are currently receiving therapy under this protocol, funding is coming to an end and the PI is leaving the institution.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-28
A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function
编号:NCT04136444登记状态:提前终止企业 / 申办者:UCB Biopharma S.P.R.L.
药物 / 成分:Padsevonil
登记的停止原因(原文):Based on available data, UCB has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizures
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-28
The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors
编号:NCT04312282登记状态:提前终止企业 / 申办者:Odonate Therapeutics, Inc.
药物 / 成分:Tesetaxel、Tesetaxel、Itraconazole、Rifampin
登记的停止原因(原文):The Sponsor has discontinued the development of tesetaxel
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-27
Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy
编号:NCT02930343登记状态:提前终止企业 / 申办者:Jawaharlal Institute of Postgraduate Medical Education & Research
药物 / 成分:Methotrexate、Leflunomide、Hydroxychloroquine、Prednisolone
登记的停止原因(原文):Due to time constraints, the study was halted prematurely
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-27
The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis
编号:NCT03040427登记状态:提前终止企业 / 申办者:The Cleveland Clinic
药物 / 成分:F-18 florbetapir
登记的停止原因(原文):Low enrollment
查看官方原始记录 ↗